1
Clinical Trials associated with AZD0240Open-label, Phase 1, Multi-Center Master Protocol to Evaluate the Safety and Preliminary Anti-Tumor Activity of TCR-engineered T Cells Recognizing KRAS Mutations in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors
Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.
100 Clinical Results associated with AZD0240
100 Translational Medicine associated with AZD0240
100 Patents (Medical) associated with AZD0240
100 Deals associated with AZD0240